Skip to Content
Merck
  • Age-dependent neonatal intracerebral hemorrhage in plasminogen activator inhibitor 1 knockout mice.

Age-dependent neonatal intracerebral hemorrhage in plasminogen activator inhibitor 1 knockout mice.

Journal of neuropathology and experimental neurology (2014-04-09)
Philippe Leroux, Priscilla L Omouendze, Vincent Roy, Nathalie Dourmap, Bruno J Gonzalez, Carole Brasse-Lagnel, Peter Carmeliet, Isabelle Leroux-Nicollet, Stéphane Marret
ABSTRACT

Intracerebral-intraventricular hemorrhages (ICH/IVH) in very preterm neonates are responsible for high mortality and subsequent disabilities. In humans, tissue plasminogen activator (t-PA) initiates fibrinolysis and activates endoluminal-endothelial receptors; dysfunction of the t-PA inhibitor (PAI-1) results in recurrent hemorrhages. We used PAI-1 knockout (PAI-1) mice to examine the role of t-PA in age-dependent intracranial hemorrhages as a possible model of preterm ICH/IVH. Intracortical injection of 2 μL of phosphate-buffered saline produced a small traumatic injury and a high rate of hemorrhage in PAI-1 pups at postnatal day 3 (P3) or P5, whereas it had no effect in wild-type neonates. This resulted in white matter and cortical lesions, ventricle enlargement, hyperlocomotion, and altered cortical levels of serotonin and dopamine in the adult PAI mice. N-methyl-D-aspartate receptor blockers, plasmin- and matrix metalloproteinases inhibitors reduced hemorrhage and tissue lesions. In contrast to P3 to P5, no significant hemorrhages were induced in P10 PAI-1 pups and there were no behavioral or neurochemical alterations in adulthood. These data suggest that microvascular immaturity up to P5 in mice is a determinant factor required for t-PA-dependent vascular rupture. Neonatal PAI-1 mice could be a useful ICH/IVH model for studying the ontogenic window of vascular immaturity and vascular protection against later neurodisabilities.

MATERIALS
Product Number
Brand
Product Description

Aminocaproic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
6-Aminohexanoic acid, ≥98.5% (NT)
Sigma-Aldrich
Aprotinin from bovine lung, BioUltra, 3-8 TIU/mg solid, ≥98% (SDS-PAGE)
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-7 TIU/mg solid
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-8 TIU/mg solid
Sigma-Aldrich
Aprotinin from bovine lung, saline solution, 3-7 TIU/mg protein
Sigma-Aldrich
6-Aminocaproic acid, ≥99% (titration), powder
Sigma-Aldrich
6-Aminocaproic acid, BioUltra, ≥99%
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-8 TIU/mg solid, BioReagent, suitable for cell culture
Sigma-Aldrich
Aprotinin from bovine lung
Supelco
Aminocaproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Aprotinin for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized, ~80% (HPCE), crystalline (fine), white, ≥3500 U/mg
Aprotinin solution, BRP, European Pharmacopoeia (EP) Reference Standard